Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of R89674 0.25% ophthalmic solution in healthy volunteers
NCT00223951Phase 3Completed
- Start
- Sep 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing R89674 0.25% Solution with Vehicle Control (2 arms). Primary endpoints: Adverse events at 42 days, Biomicroscopy findings at 42 days and 4 more. Started Sep 2005; status: completed.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00223951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00223951.